论文部分内容阅读
目的:探讨X射线损伤修复交叉互补基因1(XRCC1)与接受顺铂方案化疗的晚期非小细胞肺癌(NSCLC)患者疗效的关系。方法:经病理确诊的晚期非小细胞肺癌患者62例,接受含铂方案化疗至少2周期后评价疗效,采用TaqMan探针实时荧光定量聚合酶链反应(PCR)法和直接测序法对患者外周血XRCC1第399位密码子进行多态性分析,分析各基因型与晚期非小细胞肺癌患者近期疗效的相关性。结果:XRCC1399至少携带1个Gln等位基因携带者的疗效不如Arg等位基因携带者(14.81%vs.42.86%,OR=0.24,95%CI为0.049 2～0.908 7,P<0.05)。结论:XRCC1 399多态性与NSCLC患者对铂类药物化疗的敏感性相关。
Objective: To investigate the relationship between the efficacy of XRCC1 and cisplatin chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Methods: Sixty-two patients with pathologically diagnosed advanced non-small cell lung cancer (NSCLC) were evaluated for efficacy after at least two cycles of platinum-based chemotherapy. Real-time fluorescent quantitative polymerase chain reaction (PCR) and direct sequencing were performed on peripheral blood XRCC1 codon 399 polymorphism analysis of each genotype and prognosis of patients with non-small cell lung cancer in the short term efficacy of the correlation. Results: The carriers of XRCC1399 carrying at least one Gln allele were less effective than those carrying Arg alleles (14.81% vs.42.86%, OR = 0.24, 95% CI 0.049 2 to 0.908 7, P <0.05). Conclusion: The polymorphism of XRCC1 399 is associated with the sensitivity of NSCLC patients to platinum chemotherapy.